BioSpace News Archive

Scorpion Therapeutics, Inc. and Pierre Fabre Laboratories announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-721, Scorpion’s highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting epidermal growth factor receptor and ERBB2 Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.

Haemonetics Corporation and OpSens, Inc. announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

Cytovance Biologics announced a strategic, international collaboration with Vectron Biosolutions to add customized E. coli strain development to the CDMO’s microbial program.

BioMap announced today a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform.

SprintRay Inc. announced the launch of OnX Tough 2, the first and only 3D printing resin with US Food and Drug Administration 510 clearance for fixed, implant-supported denture prosthetics, marking a major step for the dental industry.

Merck, known as MSD outside of the United States and Canada, announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society for Medical Oncology Congress 2023 in Madrid, Spain, from Oct. 20-24.

The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine.

Bio-Techne Corporation announced that management will host a conference call and webcast on Tuesday, October 31, 2023, at 8:00 a.m. CDT to review first quarter fiscal 2024 financial results.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET.

Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter ended August 31, 2023.